Revolution Medicines (RVMDW) Expected to Announce Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMDW) will likely be announcing its results after the market closes on Wednesday, November 4th. Analysts expect Revolution Medicines to post earnings of ($2.3451) per share and revenue of $25.58 million for the quarter.

Revolution Medicines Price Performance

Shares of RVMDW traded down $0.05 during trading hours on Wednesday, reaching $9.27. The company’s stock had a trading volume of 129 shares, compared to its average volume of 95,627. Revolution Medicines has a 1-year low of $0.34 and a 1-year high of $13.44. The company has a 50 day moving average of $10.85 and a two-hundred day moving average of $6.52.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company’s research is centered on the RAS signaling pathway, which is frequently altered in tumors and has historically been difficult to target with medicines.

Revolution Medicines is developing a pipeline of RAS(ON) inhibitors designed to block active RAS proteins and related signaling. Its investigational programs include daraxonrasib (RMC-6236), an oral, broad-spectrum RAS(ON) inhibitor, as well as mutation-selective candidates such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.